CÁNCER DE MAMA
Instituto de Investigación Biomédica de Salamanca
Salamanca, EspañaPublikationen in Zusammenarbeit mit Forschern von Instituto de Investigación Biomédica de Salamanca (7)
2021
-
C3G downregulation induces the acquisition of a mesenchymal phenotype that enhances aggressiveness of glioblastoma cells
Cell Death and Disease, Vol. 12, Núm. 4
-
C3G protein, a new player in glioblastoma
International Journal of Molecular Sciences, Vol. 22, Núm. 18
2020
-
C3G is upregulated in hepatocarcinoma, contributing to tumor growth and progression and to HGF/MET pathway activation
Cancers, Vol. 12, Núm. 8, pp. 1-22
2019
-
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Aging, Vol. 11, Núm. 9, pp. 2874-2888
-
Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer
Journal of Clinical Medicine, Vol. 8, Núm. 12
-
The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin
Frontiers in Oncology, Vol. 9, Núm. MAR
2018
-
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study
Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704